Target #06Nasdaq: LABTClinical-stage antimicrobialsUnited States
LABT
Lakewood-Amedex Biotherapeutics Inc.
$0.19141.85%USD · Nasdaq, delayed
// Intel
Key numbers
Market cap$453.6K
Volume809,118
52-week high$98.20
52-week low$0.1687
From 52w high-99.81%
Shares (implied)2,369,687
1% stake costs$4.5K
Rank#6 smallest of 10
// Profile
About Lakewood-Amedex
Florida clinical-stage biotech developing Bisphosphocins, a new class of fast-acting, broad-spectrum antimicrobials aimed at resistant strains such as MRSA and VRE. Lead candidate Nu-3 has completed Phase 1 and an exploratory Phase 2, and is heading into a Phase 2a in infected diabetic foot ulcers.
Why it’s a target
About $4.3M of book equity at June 30, almost all current assets, against a market cap under $0.5M. The market is putting a negative value on a clinical-stage antibiotic pipeline.
Main risk
Binary clinical readouts, and every trial will need new money. Series C preferred is still convertible into common, and the company reverse-split 1-for-10 in June.
// The ladderLABT
- 1%Top holder$4.5KTop-holder list on most micro-caps
- 5%13D filed$22.7KSchedule 13D/13G beneficial-owner filing
- 10%Insider$45.4KSection 16 insider status
- 50.1%Control$227.2KMajority control of the vote
Costs at the last price, before market impact.
// In play